Abstract
Acromegaly is characterised by excessive levels of circulating growth hormone and its tissue mediator, insulin-like growth factor (IGF)-I. Prior to effective treatment and lowering of growth hormone and IGF-I, the majority of patients with the disease died by the age of 60 years, largely due to diabetes mellitus, cardiovascular and cerebrovascular diseases. More recently, it has become apparent that patients with acromegaly may also have an increased prevalence of colorectal adenomas and cancer. This may be due to elevated IGF-I, which is implicated in the development of sporadic colorectal cancer, and environmental factors, such as the bile acid deoxycholic acid, the levels of which are also increased in acromegaly. There is some evidence to suggest that breast and prostatic malignancies might also be increased in acromegaly. However, these associations have been based mostly on small epidemiological surveys and circumstantial evidence. Large-scale epidemiological studies are required to clarify this issue.
References
1.
Wright AD, Hill DM, Lowy C, Fraser TR: Mortality in acromegaly. QJM 1970;39:1–16.
2.
Alexander L, Appleton D, Hall R, Ross WM, Wilkinson R: Epidemiology of acromegaly in the Newcastle region. Clin Endocrinol (Oxf) 1980;12:71–79.
3.
Ezzat S, Melmed S: Clinical review 18: are patients with acromegaly at increased risk for neoplasia? J Clin Endocrinol Metab 1991;72:245–249.
4.
Jenkins PJ, Besser M: Clinical perspective: acromegaly and cancer: a problem. J Clin Endocrinol Metab 2001;86:2935–2941.
5.
Turner HE, Wass JA: Modern approaches to treating acromegaly. QJM 2000;93:1–6.
6.
Klein I, Parveen G, Gavaler JS, Vanthiel DH: Colonic polyps in patients with acromegaly. Ann Intern Med 1982;97:27–30.
7.
Pines A, Rozen P, Ron E, Gilat T: Gastrointestinal tumors in acromegalic patients. Am J Gastroenterol 1985;80:266–269.
8.
Ron E, Gridley G, Hrubec Z, Page W, Arora S, Fraumeni JF Jr: Acromegaly and gastrointestinal cancer. Cancer 1991;68:1673–1677 (erratum published in Cancer 1992;69:549).
9.
Ituarte EM, Petrini J, Hershman JM: Acromegaly and colon cancer. Ann Intern Med 1984;101:627–628.
10.
Brunner JE, Johnson CC, Zafar S, Peterson EL, Brunner JF, Mellinger RC: Colon cancer and polyps in acromegaly: increased risk associated with family history of colon cancer. Clin Endocrinol (Oxf) 1990;32:65–71.
11.
Ezzat S, Strom C, Melmed S: Colon polyps in acromegaly. Ann Intern Med 1991;114:754–755.
12.
Vasen HF, van Erpecum KJ, Roelfsema F, Raue F, Koppeschaar H, Griffioen G, et al: Increased prevalence of colonic adenomas in patients with acromegaly. Eur J Endocrinol 1994;131:235–237.
13.
Terzolo M, Tappero G, Borretta G, Asnaghi G, Pia A, Reimondo G, et al: High prevalence of colonic polyps in patients with acromegaly. Influence of sex and age. Arch Intern Med 1994;154:1272–1276.
14.
Ortego J, Vega B, Sampedro J, Escalada J, Boixeda D, Varela C: Neoplastic colonic polyps in acromegaly. Horm Metab Res 1994;26:609–610.
15.
Ladas SD, Thalassinos NC, Ioannides G, Raptis SA: Does acromegaly really predispose to an increased prevalence of gastrointestinal tumours? Clin Endocrinol (Oxf) 1994;41:597–601.
16.
Delhougne B, Deneux C, Abs R, Chanson P, Fierens H, Laurent-Puig P, et al: The prevalence of colonic polyps in acromegaly: a colonoscopic and pathological study in 103 patients. J Clin Endocrinol Metab 1995;80:3223–3226.
17.
Colao A, Balzano A, Ferone D, Panza N, Grande G, Marzullo P, et al: Increased prevalence of colonic polyps and altered lymphocyte subset pattern in the colonic lamina propria in acromegaly. Clin Endocrinol 1997;47:23–28.
18.
Archambeaud-Mouveroux F, Geffray I, Teissier MP, Galinat S, Sautereau D, Pillegand B: Prevalence of colorectal carcinoma and polyps in acromegaly (abstract). 80th Annu Meet Endocr Soc, New Orleans, June 1998, 2–504..
19.
Jenkins PJ, Fairclough PD, Richards T, Lowe DG, Monson J, Grossman A, et al: Acromegaly, colonic polyps and carcinoma. Clin Endocrinol 1997;47:17–22.
20.
Tzoiti M, Akriviadis A, Papadopoulou E, Goulis I, Papagiorgiou A, Patsiaura K, et al: Colon polyps prevalence in acromegalic patients (abstract). 82nd Annu Meet Endocr Soc, June 2000, Toronto, 2028.
21.
Terzolo M, Reimondo G, Gasperi M, Cozzi R, Pivonello R, Vitale G, et al: Colonoscopic screening and follow-up in patients with acromegaly: a multicenter study in Italy. J Clin Endocrinol Metab 2005;90:84–90.
22.
Orme SM, McNally RJ, Cartwright RA, Belchetz PE: Mortality and cancer incidence in acromegaly: a retrospective cohort study. J Clin Endocrinol Metab 1998;83:2730–2734.
23.
Atkin WS, Morson BC, Cuzick J: Long-term risk of colorectal cancer after excision of rectosigmoid adenomas. N Engl J Med 1992;326:658–662.
24.
Jenkins PJ, Frajese V, Jones AM, Camacho-Hubner C, Lowe DG, Fairclough PD, et al: IGF-I and the development of colorectal neoplasia in acromegaly. J Clin Endocrinol Metab 2000;85:3218–3221.
25.
Cats A, Dullaart RP, Kleibeuker JH, Kuipers F, Sluiter WJ, Hardonk MJ, et al: Increased epithelial cell proliferation in the colon of patients with acromegaly. Cancer Res 1996;56:523–526.
26.
Bogazzi F, Russo D, Locci MT, Chifenti B, Ultimieri F, Raggi F, et al: Apoptosis is reduced in the colonic mucosa of patients with acromegaly. Clin Endocrinol (Oxf) 2005;63:683–688.
27.
Jenkins PJ, Fairclough PD: Screening guidelines for colorectal cancer and polyps in patients with acromegaly. Gut 2002;51(suppl 5):V13–V14.
28.
Jenkins PJ, Mukherjee A, Shalet SM: Does growth hormone cause cancer? Clin Endocrinol (Oxf) 2006;64:115–121.
29.
Jenkins PJ, Mills TD, Veysey MJ, Reynolds CR, Dowling RH, Besser GM: Acromegaly is associated with colonomegaly which correlates with tissue exposure to growth hormone and may be implicated in their increased risk of colorectal neoplasia (abstract). J Endocrinol 1997;155(suppl 2):OC22.
30.
Renehan AG, Painter JE, Bell GD, Rowland RS, O’Dwyer ST, Shalet SM: Determination of large bowel length and loop complexity in patients with acromegaly undergoing screening colonoscopy. Clin Endocrinol (Oxf) 2005;62:323–330.
31.
Veysey MJ, Thomas LA, Mallet A, Jenkins PJ, Besser GM, Wass JAH, et al: Prolonged large bowel transit increases serum deoxycholic acid: a risk factor for octreotide induced gallstones. Gut 1999;44:675–681.
32.
Renehan AG, Bhaskar P, Painter JE, O’Dwyer ST, Haboubi N, Ball SG, et al: The prevalence and characteristics of colorectal neoplasia in acromegaly. J Clin Endocrinol Metab 2000;85:3417–3424.
33.
Manousos O, Souglakos J, Bosetti C, Tzonou A, Chatzidakis V, Trichopoulos D, et al: IGF-I and IGF-II in relation to colorectal cancer. Int J Cancer 1999;83:15–17.
34.
Ma J, Pollak M, Giovannucci E, Chan JM, Tao Y, Hennekens CH, et al: Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-1 and IGF-binding protein-3. J Natl Cancer Inst 1999;91:620–625.
35.
Veysey MJ, Thomas LA, Mallet AI, Jenkins PJ, Besser GM, Murphy GM, et al: Colonic transit influences deoxycholic acid kinetics. Gastroenterology 2001;121:812–822.
36.
Nabarro JD: Acromegaly. Clin Endocrinol (Oxf) 1987;26:481–512.
37.
Bengtsson BA: Acromegaly and neoplasia. J Pediatr Endocrinol 1993;6:73–78.
38.
Emerman JT, Leahy M, Gout PW, Bruchovsky N: Elevated growth hormone levels in sera from breast cancer patients. Horm Metab Res 1985;17:421–424.
39.
Peyrat JP, Bonneterre J, Hecquet B, Vennin P, Louchez MM, Fournier C, et al: Plasma insulin-like growth factor-1 (IGF-1) concentrations in human breast cancer. Eur J Cancer 1993;29A:492–497.
40.
Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, et al: Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998;351:1393–1396.
41.
Renehan AG, Zwahlen M, Minder C, O’Dwyer ST, Shalet SM, Egger M: Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 2004;363:1346–1353.
42.
Moon HD, Simpson ME, Li CH, Evans HM: Neoplasms in rats treated with pituitary growth hormone I. Pulmonary and lymphatic tissues. Cancer Res 1950;10:297–308.
43.
Ray BS, Pearson OH: Hypophysectomy in treatment of disseminated breast cancer. Surg Clin North Am 1962;12:419–433.
44.
Pollak MN: Endocrine effects of IGF-I on normal and transformed breast epithelial cells: potential relevance to strategies for breast cancer treatment and prevention. Breast Cancer Res Treat 1998;47:209–217.
45.
Ng ST, Zhou J, Adesanya OO, Wang J, LeRoith D, Bondy CA: Growth hormone treatment induces mammary gland hyperplasia in aging primates. Nature 1998;3:1141–1144.
46.
Tornell J, Carlsson B, Pohjanen P, Wennbo H, Rymo L, Isaksson O: High frequency of mammary adenocarcinomas in metallothionein promoter-human growth hormone transgenic mice created from two different strains of mice. J Steroid Biochem Mol Biol 1992;43:237–242.
47.
Yang XF, Beamer WG, Huynh H, Pollak M: Reduced growth of human breast cancer xenografts in hosts homozygous for the lit mutation. Cancer Res 1996;56:1509–1511.
48.
Colao A, Marzullo P, Ferone D, Spiezia S, Cerbone G, Marino V, et al: Prostatic hyperplasia: an unknown feature of acromegaly. J Clin Endocrinol Metab 1998;83:775–779.
49.
le Roux CW, Monson JP, Chew SL, Grossman AB, Besser GM, Jenkins PJ: Increased serum prostate-specific antigen in acromegaly – a cross-sectional study (abstract). J Endocrinol 2000;164(suppl):P128.
50.
Wolk A, Mantzoros CS, Andersson SO, Bergstrom R, Signorello LB, Lagiou P, et al: Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. J Natl Cancer Inst 1998;90:911–915.
51.
Mantzoros CS, Tzonou A, Signorello LB, Stampfer M, Trichopoulos D, Adami HO: Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. Br J Cancer 1997;76:1115–1118.
52.
Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, et al: Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998;279:563–566.
53.
Barzilay J, Heatley GJ, Cushing GW: Benign and malignant tumors in patients with acromegaly. Arch Intern Med 1991;151:1629–1632.
54.
Cheung NW, Boyages SC: Increased incidence of neoplasia in females with acromegaly. Clin Endocrinol (Oxf) 1997;47:323–327.
55.
Popovic V, Damjanovic S, Micic D, Nesovic M, Djurovic M, Petakov M, et al: Increased incidence of neoplasia in patients with pituitary adenomas. The Pituitary Study Group. Clin Endocrinol (Oxf) 1998;49:441–445.
56.
Ziel FH, Peters AL: Acromegaly and gastrointestinal adenocarcinomas. Ann Intern Med 1988;109:514–515.
© 2006 S. Karger AG, Basel
2006
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
